Publication Name	World Journal of Clinical Oncology
Manuscript ID	8492
Country	Australia

Received	2013-12-29 14:38
Peer-Review Started	2013-12-29 15:24
To Make the First Decision	2014-01-15 16:24
Return for Revision	2014-01-20 13:11
Revised	2014-02-17 19:52
Second Decision	2014-05-14 16:28
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-05-14 16:40
Articles in Press	2014-05-23 09:09
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-07-24 14:14
Publish the Manuscript Online	2014-08-01 16:16

ISSN	2218-4333 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Advances in adjuvant systemic therapy for non-small-cell lung cancer
Manuscript Source	Invited Manuscript
All Author List	David Leong, Rajat Rai, Brandon Nguyen, Andrew Lee and Desmond Yip
Funding Agency and Grant Number
Corresponding Author	David Leong, MBBS, FRACP, Department of Medical Oncology, The Canberra Hospital, Yamba Drive, Garran, ACT 2605, Australia. david.leong@act.gov.au
Key Words	Carcinoma; Non-small-cell lung; Chemotherapy; Adjuvant; Radiotherapy; Biological therapy; Biomarker
Core Tip	Improvement in survivals of patients with resected non-small lung cancer has been rather modest. Adjuvant systemic chemotherapy with high dose cisplatin and vinorelbine has been established to be beneficial in improving disease free and overall survival in stage Ⅱ and ⅢA but not stage Ⅰ patients. This benefit is observed also in elderly patients. Post-operative radiation therapy has a deleterious effect on early stage tumour but appears to improve survival and reduce local recurrence in higher risk stage Ⅲ or N2 disease with modern techniques. The availability of targeted biologicals and biomarker development may allow future selection of high risk groups who benefit from adjuvant treatments.
Publish Date	2014-08-01 16:16
Citation	Leong D, Rai R, Nguyen B, Lee A, Yip D. Advances in adjuvant systemic therapy for non-small-cell lung cancer. World J Clin Oncol 2014; 5(4): 633-645
URL	http://www.wjgnet.com/2218-4333/full/v5/i4/633.htm
DOI	http://dx.doi.org/10.5306/wjco.v5.i4.633

Full Article (PDF)	WJCO-5-633.pdf
Full Article (Word)	WJCO-5-633.doc
Manuscript File	8492-Review.doc
Answering Reviewers	8492-Answering reviewers.pdf
Copyright License Agreement	8492-Copyright assignment.pdf
Peer-review Report	8492-Peer review(s).pdf
Scientific Editor Work List	8492-Scientific editor work list.pdf